|Table of Contents|

The research status of tumor markers related to prognosis of head and neck squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
888-892
Research Field:
Publishing date:

Info

Title:
The research status of tumor markers related to prognosis of head and neck squamous cell carcinoma
Author(s):
QIAN Chengcheng; YUAN Haihua; JIANG Bin
Department of Oncology,Ninth People's Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 201900,China.
Keywords:
head and neck squamous carcinoma; tumor marker; prognosis; Cyfra21-1; SCCAg; TPS; CTCs
PACS:
R739.91
DOI:
10.3969/j.issn.1672-4992.2021.05.038
Abstract:
In recent years,great progress has been made in the treatment of head and neck squamous cell carcinoma.Disease control and the quality of life of patients can be greatly improved through surgery,radiotherapy or chemotherapy.But the overall survival rate is still very low,mainly because of the recurrence and distant metastasis.If the clinicians have some tools for the detection of local recurrence and metastasis,the patients will accept the treatments at the early stage.However,for the patients with head and neck squamous cell carcinoma,it has become a major concern to find a reliable tumor marker to assist clinical diagnosis,judge patients' response of treatment and early detection of local recurrence.This review mainly describes tumor markers that are likely to be prognostic for head and neck squamous cell carcinoma.

References:

［1］TRAVASSOS DC.Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma:Systematic review and meta-analysis［J］.Journal of Oral Pathology & Medicine,2018,47(1):3-10.
［2］SAWANT SS,ZINGDE SM,VAIDYA MM.Cytokeratin fragments in the serum:their utility for the management of oral cancer［J］.Oral Oncol,2008,44(8):722-732.
［3］SPROLL C,FLUEGEN G,STOECKLEIN NH.Minimal residual disease in head and neck cancer and esophageal cancer［J］.Adv Exp Med Bio,2018（1100）:55-82.
［4］袁川淑.血清肿瘤标志物Cyfra21-1、SCCAg、Ferritin、CEA、CA19-9和AFP对口腔/口咽鳞癌的诊断价值 ［D］.重庆:重庆医科大学,2016. YUAN CS.The diagnostic value of serum tumor markers Cyfra21-1,SCCAg,Ferritin,CEA,CA19-9 and AFP in oral/oropharyngeal squamous cell carcinoma［D］.Chongqing:Chongqing Medical University,2016.
［5］WU XL,TU Q,FAURE G,et al.Diagnostic and prognostic value of circulating tumor cells in head and neck squamous cell carcinoma:a systematic review and meta-analysis［J］.Sci Rep,2016,6(1):398-406.
［6］KULASINGHE A,KENNY L,PUNYADEERA C.Circulating tumour cell PD-L1 test for head and neck cancers［J］.Oral Oncol,2017,75:6-7.
［7］NAGLER RM,BARAK M,PELED M,et al.Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma［J］.Cancer,1999,85(5):1018-1025.
［8］ 朱焕锋,严鹏伟,宗丹,等.8例头颈部鳞状细胞癌根治术后调强放疗后局部复发模式分析［J］.肿瘤学杂志,2017,23(08):722-724. ZHU HF,YAN PW,ZONG D,et al.Patterns of local recurrence for 8 cases with squamous cell carcinoma of head and neck after definitive surgery and IMRT［J］.Journal of Chinese Oncology,2017,23(08):722-724.
［9］AMIN MB,GREENE FL,EDGE SB,et al.The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging［J］.CA Cancer J Clin,2017,67(2):93-99.
［10］D DEP,YOUNG CK,CHIEN HT,et al.Prognostic roles of SCC antigen,CRP and CYFRA 21-1 in oral cavity squamous cell carcinoma［J］.Anticancer Res,2019,39(4):2025-2033.
［11］陈允硕.肿瘤标志物的临床应用价值［J］.中华检验医学杂志,2000,23(01):51-54. CHEN YS.Clincal value of tumor markers［J］.Chinese Journal of Laboratory Medicine,2000,23(01):51-54.
［12］DOWECK I,BARAK M,GREENBERG E,et al.Cyfra 21-1:A new potential tumor marker for squamous cell carcinoma of head and neck［J］.Arch Otolaryngol Head Neck Surg,1995,121(2):177-181.
［13］RUDHART SA,SCHULTZ JD,GEHRT F,et al.CYFRA 21-1:a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma［J］.Eur Arch Otorhinolaryngol,2019,276(12):3467-3475.
［14］ 饶丽华,张茏,田令,等.喉癌患者CEA、Cyfra21-1、SCC检测与临床病理指标关系［J］.临床耳鼻咽喉头颈外科杂志,2017,31(15):1182-1186. RAO LH,ZHANG L,TIAN L,et al.The clinical signifinace of CEA,Cyfra 21-1 and SCC in laryngeal carcinoma's clinicopathological parameters［J］.J Clin Otorhinolaryngol Head Neck Surg,2017,31(15):1182-1186.
［15］ 王继生,孙艳.头颈部鳞状细胞癌血清SCC、CYFRA21-1、NSE、CEA联合检测的临床意义［J］.肿瘤研究与临床,2009,21(6):396-398. WANG JS,SUN Y.Clinical value of combined detection of tumor markers for nasopharyngeal carcinoma and squamous cell carcinoma in head and neck［J］.Cancer Research and Clinc,2009,21(6):396-398.
［16］CAMPTON DE,RAMIREZ AB,NORDBERG JJ,et al.High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining［J］.BMC Cancer,2015,15:360.
［17］郝瑞,梁艳.口腔鳞状细胞癌患者血清cyfra21-1水平变化及其与患者临床病理特征及预后的相关性研究［J］.肿瘤学杂志,2018,24(12):1176-1180. HAO R,LIANG Y.Correlation between serum Cyfra21-1 levels and clinicopathological features and prognosis in patients with oral squamous cell carcinoma［J］.Journal of Chinese Oncology,2018,24(12):1176-1180.
［18］IMAI R,TAKENAKA Y,YASUI T,et al.Prognostic significance of serum squamous cell carcinoma antigen in patients with head and neck cancer［J］.Acta Otolaryngol,2015,135(3):295-301.
［19］LIN WH,CHEN IH,WEI FC,et al.Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma［J］.Laryngoscope,2011,121(5):971-977.
［20］JANTHARAPATTANA K,KOTAMNIVATES T,HIRUNPAT S,et al.Correlation between serum squamous cell carcinoma antigen level and tumor volume in head and neck cancer［J］.ORL J Otorhinolaryngol Relat Spec,2018,80(5-6):284-289.
［21］韩淼,周长明,思超,等.喉癌患者血清中SCCAg、CEA、CA19-9、CA72-4和CYFRA21-1的检测及意义［J］.实用癌症杂志,2017,32(09):1434-1437. HAN M,ZHOU CM,SI C,et al.Detection value and significance of SCCAg,CEA,CA19-9,CA72-4 and CYFRA21-1 in patients with laryngeal carcinoma［J］.The Practical Journal of Cancer,2017,32(09):1434-1437.
［22］HUANG SF,WEI FC,LIAO CT,et al.Risk stratification in oral cavity squamous cell carcinoma by preoperative CRP and SCC antigen levels［J］.Ann Surg Oncol,2012,19(12):3856-3864.
［23］TRAVASSOS DC,FERNANDES D,MASSUCATO EMS,et al.Squamous cell carcinoma antigen as a prognostic marker and its correlation with clinicopathological features in head and neck squamous cell carcinoma:Systematic review and meta-analysis［J］.J Oral Pathol Med,2018,47(1):3-10.
［24］李伟.血清SCC-Ag、CYFRA21-1在喉鳞状细胞癌患者中的表达及临床意义［D］.广西：广西医科大学,2019. LI W.Expression and clinical significance of pretreatment serum SCC-Ag and CYFRA21-1 in patients with laryngeal squamous cell carcinoma［D］.Guangxi:Guangxi Medical University,2019.
［25］KALFERT D,LUDVIK J,KUCERA R,et al.Pretreatment serum levels of soluble cytokeratin fragments (Cyfra 21-1,TPS,MonoTotal) in relation to clinical and pathobiological aspects of head and neck squamous cell carcinomas［J］.Anticancer Res,2019,39(9):5171-5177.
［26］李海如,郑健,吴蕾,等.口腔鳞癌患者血清TPS水平变化及意义［J］.山东医药,2014,54(20):83,111. LI HR,ZHENG J,WU L,et al.Changes and sinificance of serum TPS level in patients with oral squamous cell carcinoma［J］.Shandong Medical Journal,2014,54(20):83,111.
［27］张岱,李延卿,高云,等.TPS、CEA、SCC-Ag及CYFRA21-1评估头颈部肿瘤的应用价值［J］.江苏医药,2017,43(01):68-70. ZHANG D,LI YQ,GAO Y,et al.To evaluate the application value of head and neck tumor by TPS,CEA,SCC-Ag and CYFRA21-1［J］.Jiangsu Medical Journal,2017,43(01):68-70.
［28］BARAK V,MEIROVITZ A,LEIBOVICI V,et al.The diagnostic and prognostic value of tumor markers (CEA,SCC,CYFRA 21-1,TPS) in head and neck cancer patients［J］.Anticancer Res,2015,35(10):5519-5524.
［29］周晴接,杨建民.循环肿瘤细胞研究进展［J］.世界华人消化杂志,2010,18(11):1081-1087. ZHOU QJ,YANG JM.Advances in the research of circulating tumor cells［J］.World Chinese Journal of Digestology,2010,18(11):1081-1087.
［30］ECONOMOPOULOU P,KOTSANTIS I,KYRODIMOS E,et al.Liquid biopsy:An emerging prognostic and predictive tool in head and neck squamous cell carcinoma (HNSCC):Focus on circulating tumor cells (CTCs)［J］.Oral Oncol,2017,74:83-89.
［31］JATANA KR,BALASUBRAMANIAN P,LANG JC,et al.Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck:initial results［J］.Arch Otolaryngol Head Neck Surg,2010,136(12):1274-1279.
［32］KULASINGHE A,HUGHES BGM,KENNY L,et al.An update:circulating tumor cells in head and neck cancer［J］.Expert Rev Mol Diagn,2019,19(12):1109-1115.
［33］WANG Z,CUI K,XUE Y,et al.Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck:a systematic review and meta-analysis［J］.Med Oncol,2015,32(5):164.
［34］GRISANTI S,ALMICI C,CONSOLI F,et al.Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma:prognostic and predictive significance［J］.PLoS One,2014,9(8):e103918.
［35］BANAL A,HACENE K,BERTHELOT-RUFF E,et al.Comparison of Cyfra 21-1 and SCC assays in head and neck tumours［J］.Tumour Biol,2001,22(1):27-35.
［36］CHEN HH,WANG HM,FAN KH,et al.Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma［J］.PLoS One,2013,8(1):e55327.
［37］ADEL M,TSAO CK,WEI FC,et al.Preoperative SCC antigen,CRP serum levels,and lymph node density in oral squamous cell carcinoma［J］.Medicine (Baltimore),2016,95(14):e3149.
［38］O'BRIEN CJ,TRAYNOR SJ,MCNEIL E,et al.The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx［J］.Arch Otolaryngol Head Neck Surg,2000,126(3):360-365.

Memo

Memo:
上海交通大学医学院附属第九人民医院种子基金(编号：JYZZ008G）
Last Update: 2021-01-29